援助如何运作
通过无与伦比的全方位服务便利性，简化患者的专业药房体验
-
1. 检查您的保险范围/福利验证
我们的专业出纳员团队会找到最佳的保险途径，以最大程度地减少自付费用。
-
2. 将处方转移到 AmeriPharma®
我们与您之前的药房或处方人员合作来处理您的处方，使过渡变得快速而简单。
-
3. 事先授权
我们的专家团队将在 24 至 72 小时内获得您保险公司的批准。
-
4. 共付额援助和经济援助
我们确保患者获得经济援助，并降低共付额、自付费用和高额免赔额。迄今为止，AmeriPharma® 专科护理已为患者争取到 1TP4.4755 亿美元的经济援助。
-
5. 必要时的护理协调
AmeriPharma® 在安排和协调我们的专业护士为您进行家庭输液时，会将您的日程安排和家庭环境放在首位。
-
6. 交付协调
药品始终严格遵守运输的具体要求。次日或隔夜冷链配送将根据您的时间安排进行协调。
Vonvendi是什么？
Vonvendi is an FDA-approved recombinant von Willebrand factor (VWF) medicine. In adults and children with 血管性血友病 (VWD), it is used for on-demand treatment and control of bleeding episodes and for perioperative management of bleeding. In adults, Vonvendi is also approved for routine preventive treatment (prophylaxis) to reduce the frequency of bleeding episodes.
The FDA first approved Vonvendi in the United States in 2015. Unlike plasma-derived VWF products, such as Humate-P, Vonvendi contains recombinant VWF and is not derived from human plasma.
Vonvendi 为粉末状，使用前需与无菌水混合，然后通过静脉注射（IV）给药。.
Vonvendi 的用途是什么？
Vonvendi is FDA-approved for certain uses in adults and children with von Willebrand disease (VWD), although not all approved uses apply to both age groups. Vonvendi contains a recombinant version of VWF, a protein that plays an important role in blood clotting. It temporarily replaces deficient or dysfunctional VWF in people with VWD. Vonvendi is FDA-approved for:
按需治疗和控制出血发作： 患有血管性血友病 (VWD) 的患者在出现出血需要补充血管性血友病因子 (VWF) 时可以使用 Vonvendi。根据出血的严重程度和部位，可能需要多次给药。.
手术周围出血的处理： Vonvendi 可在手术前、手术中和手术后使用，以帮助控制出血。.
出血的常规预防性治疗： Adults with VWD can receive Vonvendi regularly as routine prophylaxis to reduce the frequency of bleeding episodes.
请注意，Vonvendi 并不能治愈血管性血友病 (VWD)。它的作用是暂时替代缺失或缺陷的血管性血友病因子 (VWF)，帮助您的身体控制出血。.
How Vonvendi Copay Assistance Works
AmeriPharma® 特药药房减轻了患者及其家人的经济负担
-
先进的软件可以定位资金来源，为您匹配高额的基金会项目
-
我们的一位共付额援助专家将协助您完成申请流程
-
自动更新信息将发送给您和您的医生，告知您资金状况
Vonvendi 剂量
Vonvendi comes as a powder that is reconstituted before administration and is given intravenously. Dosing is individualized according to factors such as body weight, the type and severity of bleeding, the clinical situation, and VWF and factor VIII levels. Your healthcare provider will determine the appropriate dose and treatment schedule. The following summarizes dosing recommendations from the prescribing information:
用于按需治疗和控制出血发作： 对于轻微出血，例如鼻出血或口腔出血，建议初始剂量为 40–50 IU/kg。后续剂量可根据临床需要每 8–24 小时给予 40–50 IU/kg。.
For major bleeding, the recommended initial dose is 50–80 IU/kg. Subsequent doses of 40–60 IU/kg may be administered every 8–24 hours for approximately 2–3 days, or as clinically required.
对于手术： Perioperative dosing is individualized according to the type of surgery and the patient’s VWF and factor VIII levels. For elective surgery, a preoperative dose of Vonvendi may be given 12–24 hours before surgery when needed to allow the patient’s factor VIII level to increase. VWF and factor VIII levels are assessed before surgery, and an additional dose may be administered within 1 hour before the procedure to achieve appropriate target levels. Emergency surgery and postoperative dosing require individualized management based on factor levels and clinical response.
用于常规预防性治疗： The recommended dose for adults is 40–60 IU/kg twice weekly.
Vonvendi 副作用
常见的副作用包括：
- 头痛
- 呕吐
- 恶心
- 头晕
- 瘙痒
严重副作用：
Vonvendi can cause serious adverse reactions. Important risks and warnings include hypersensitivity reactions, thromboembolic events, and the development of neutralizing antibodies (inhibitors).
超敏反应： Severe allergic reactions, including anaphylaxis, can occur with Vonvendi. Signs and symptoms may include hives, generalized itching, swelling, difficulty breathing, rapid heartbeat, chest tightness, dizziness, or low blood pressure. Stop the infusion and seek immediate medical attention if signs of a severe allergic reaction occur.
血栓（血栓栓塞事件）： Blood clots in arteries or veins have occurred in patients receiving Vonvendi, particularly in people with risk factors for thrombosis. Your healthcare provider may monitor you for signs of blood clots and may also monitor factor VIII levels when Vonvendi is given with recombinant factor VIII. Seek prompt medical attention for symptoms such as chest pain, shortness of breath, or pain or swelling in an arm or leg.
抑制剂的开发： Neutralizing antibodies (inhibitors) against VWF and/or factor VIII can develop during treatment. If expected VWF activity or factor VIII levels are not achieved, or if bleeding is not controlled with an appropriate dose, your healthcare provider may perform tests for inhibitors.
请注意，这并非所有可能副作用的完整列表。如果您服用 Vonvendi 后出现任何严重副作用，请立即联系您的医生。.
接受保险
我们接受 Medicare、跨州 Medicaid、Medi-Cal、Blue Shield 以及大多数私人保险。请致电我们，了解更多您的保险信息。
